Home » Stocks » RFL

Rafael Holdings, Inc. (RFL)

Stock Price: $25.25 USD -0.63 (-2.43%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 409.72M
Revenue (ttm) 4.75M
Net Income (ttm) -10.26M
Shares Out 15.82M
EPS (ttm) -0.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $25.25
Previous Close $25.88
Change ($) -0.63
Change (%) -2.43%
Day's Open 25.44
Day's Range 24.08 - 26.00
Day's Volume 46,169
52-Week Range 10.40 - 26.29

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 days ago

CRANBURY, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announc...

PRNewsWire - 1 month ago

NEWARK, N.J., Dec. 15, 2020 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.1 million and a loss per share of $0.09 for the first quarter of its 2021 fiscal year, th...

GlobeNewsWire - 1 month ago

CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced tod...

GlobeNewsWire - 1 month ago

CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced tod...

GlobeNewsWire - 1 month ago

CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) --   Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today annou...

GlobeNewsWire - 1 month ago

CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announc...

GlobeNewsWire - 2 months ago

CRANBURY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced tod...

PRNewsWire - 2 months ago

NEWARK, N.J., Oct. 29, 2020 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $4.9 million and a loss per share of $0.66 for the fiscal year ended July 31, 2020. Fourth q...

GlobeNewsWire - 2 months ago

Company to launch clinical trial in clear cell sarcoma, a subtype of soft tissue sarcoma, in the coming months Company to launch clinical trial in clear cell sarcoma, a subtype of soft tissue ...

GlobeNewsWire - 2 months ago

CRANBURY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics announced toda...

GlobeNewsWire - 5 months ago

One of the largest active Phase 3 clinical trials in metastatic pancreatic cancer, completes target enrollment ahead of schedule One of the largest active Phase 3 clinical trials in metastati...

GlobeNewsWire - 5 months ago

Despite the COVID-19 pandemic, clinical trial for AML continues to actively enroll patients, with established safety precautions Despite the COVID-19 pandemic, clinical trial for AML continues...

PRNewsWire - 7 months ago

NEWARK, N.J., June 9, 2020 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.2 million and a loss per share of $0.14 for the fiscal quarter ended April 30, 2020. Q3 FY...

GlobeNewsWire - 7 months ago

Cranbury, NJ, May 26, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announc...

GlobeNewsWire - 8 months ago

Company advances mission to combat AML, as this research comes on the heels of its Phase 3 trial, actively enrolling globally Company advances mission to combat AML, as this research comes on ...

GlobeNewsWire - 8 months ago

Cranbury, NJ, May 05, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announce...

GlobeNewsWire - 8 months ago

Patients will be assessed in advance of enrollment to ensure safety, due to COVID-19 pandemic Patients will be assessed in advance of enrollment to ensure safety, due to COVID-19 pandemic

GlobeNewsWire - 8 months ago

Patient enrollment will begin only once local health officials determine that it is safe, in light of the COVID-19 pandemic Patient enrollment will begin only once local health officials deter...

GlobeNewsWire - 9 months ago

COVID-19 task force established to support enrolled patients Participating medical centers implemented safety measures and currently enrolling patients COVID-19 task force established to suppo...

GlobeNewsWire - 10 months ago

Dr. Sehgal joins Rafael Pharmaceuticals to lead the growth of regulatory affairs Dr. Sehgal joins Rafael Pharmaceuticals to lead the growth of regulatory affairs

GlobeNewsWire - 11 months ago

Study authors found that Promitil may be a useful agent in patients with metastatic colorectal cancer (CRC) Study authors found that Promitil may be a useful agent in patients with metastatic ...

GlobeNewsWire - 11 months ago

Clinical trial further bolsters company’s pipeline in and focus on gastrointestinal cancers Clinical trial further bolsters company’s pipeline in and focus on gastrointestinal cancers

GlobeNewsWire - 1 year ago

Clinical trial using devimistat in combination with FOLFIRINOX as first-line treatment has enrolled more than 250 patients ahead of scheduled timeline Clinical trial using devimistat in combin...

GlobeNewsWire - 1 year ago

President and CEO Sanjeev Luther to discuss the status of clinical trials for lead compound CPI-613® (devimistat) and provide update on drug development pipeline President and CEO Sanjeev Luth...

GlobeNewsWire - 1 year ago

Cranbury, NJ, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced tod...

GlobeNewsWire - 1 year ago

Cranbury, NJ, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced tod...

GlobeNewsWire - 1 year ago

Cranbury, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today annou...

GlobeNewsWire - 1 year ago

Cranbury, NJ, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced tod...

GlobeNewsWire - 1 year ago

Dr. Costa Filho joins alongside Timothy Pardee, M.D., Ph.D, who will remain as Co-Chief Medical Officer Dr. Costa Filho joins alongside Timothy Pardee, M.D., Ph.D, who will remain as Co-Chief ...

GlobeNewsWire - 1 year ago

Cranbury, NJ, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announc...

GlobeNewsWire - 1 year ago

Cranbury, NJ, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announc...

GlobeNewsWire - 1 year ago

Cranbury, NJ, Oct. 17, 2019 (GLOBE NEWSWIRE) --   Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced ...

GlobeNewsWire - 1 year ago

CRANBURY, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today anno...

GlobeNewsWire - 1 year ago

CRANBURY, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today anno...

GlobeNewsWire - 1 year ago

Cranbury, NJ, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced tod...

About RFL

Rafael Holdings owns commercial real estate assets and interests in pre-clinical and clinical stage pharmaceutical companies. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Industry
Biotechnology
CEO
Howard S. Jonas
Employees
54
Stock Exchange
NYSE
Ticker Symbol
RFL
Full Company Profile

Financial Performance

In 2020, RFL's revenue was $4.91 million, a decrease of -0.43% compared to the previous year's $4.93 million. Losses were -$10.42 million, 121.9% more than in 2019.

Financial Statements